THIRD QUARTER 2022
- Net sales amounted to
SEK 257.7 million (173.8), an increase ofSEK 83.9 million , or 48% (excluding foreign exchange effects, 33%) of which the acquisition of Nutraceutics accounted for an increase ofSEK 20.8 million (12%). Organic growth was 21%. -
Net sales in the Paediatrics segment amounted to
SEK 205.7 million (130.8), an increase of 57% (excluding foreign exchange effects, 41%). -
Net sales in the
Adult Health segment amounted toSEK 50.5 million (42.1), an increase of 20% (excluding foreign exchange effects, 7%). -
Operating expenses amounted to
SEK 92.0 million (60.7), an increase ofSEK 31.4 million , (52%), of which the acquisition of Nutraceutics accounted for an increase ofSEK 24.2 million (40%). Operating expenses included costs for evaluating acquisition candidates ofSEK 0.0 million (0.1). -
Operating profit increased by 40% to
SEK 93.7 million (67.2), which corresponds to an operating margin of 36% (39%). -
Profit after tax amounted to
SEK 79.5 million (52.8), an increase of 50%. -
Earnings per share amounted to
SEK 0.79 (0.52) before and after dilution[2]. -
Cash flow amounted to
SEK 37.3 million (55.6). -
Cash and cash equivalents at
30 September 2022 amounted toSEK 1,402.4 million (1,529.7).
Key events in the third quarter of 2022
On 14 July, BioGaia announced that results for the second quarter exceeded market expectations.
On 29 August, BioGaia announced that it has built a pilot plant in Eslöv,
On 22 September, BioGaia announced that BioGaia and Skinome have collaborated on the research and development of a product with live bacteria that can improve skin health in a natural way by supporting the skin microbiome.
JANUARY -
- Net sales amounted to
SEK 829.7 million (578.9), an increase ofSEK 250.7 million , or 43% (excluding foreign exchange effects, 32%) of which the acquisition of Nutraceutics accounted for an increase ofSEK 50.2 million (9%). Organic growth was 24%. -
Net sales in the Paediatrics segment amounted to
SEK 661.0 million (453.6), an increase of 46% (excluding foreign exchange effects, 34%). -
Net sales in the
Adult Health segment amounted toSEK 165.5 million (121.7), an increase of 36% (excluding foreign exchange effects, 26%). -
Operating expenses amounted to
SEK 303.6 million (223.2), an increase ofSEK 80.3 million (36%), of which the acquisition of Nutraceutics accounted for an increase ofSEK 67.6 million (30%). -
Operating expenses included costs of evaluation of acquisition candidates of
SEK 1.1 million (2.6), restructuring costs (relating to personnel) ofSEK 3.9 million (2.4) and the reversal of previous impairment of right-of-use assets linked to a rental contract for premises ofSEK -1.7 million (5.1). Excluding these items, operating expenses amounted toSEK 300.3 million (213.2), an increase of 41%. -
Operating profit increased by 45% to
SEK 290.3 million (200.6), which corresponds to an operating margin of 35% (35%). -
Profit after tax amounted to
SEK 234.3 million (158.0), an increase of 48%. -
Earnings per share amounted to
SEK 2.32 (1.56) before and after dilution[2]. -
Cash flow amounted to
SEK -101.8 million (56.7).
Key events after the end of the third quarter
On 17 October, BioGaia announced that profit for the third quarter exceeded market expectations.
[2] In view of the 5:1 share split, which took place in
CEO'S COMMENTS
It is very gratifying to present another strong quarter, which is the fifth consecutive quarter with double-digit growth. BioGaia increased net sales by 48% compared with the year-earlier quarter with an operating margin of 36%. The Paediatrics segment increased 57% and the
In our
In EMEA,
APAC reported double-digit sales growth in
As part of our strategy to control our entire value chain, we started a pilot fermentation plant where we will test the manufacturing of bacteria strains that are extremely oxygen-sensitive.
As we look back on another strong quarter, we feel well prepared to get through the very uncertain times ahead. We are continuing our prioritised strategy to selectively increase our marketing to consumers.
People will always prioritise good health and we remain optimistic about the future. Together, we are creating an innovative workplace where employees are enthusiastic and strive towards the same vision: to become the world's most trusted probiotic brand.
CEO BioGaia
Teleconference:
Investors, analysts and the media are invited to take part in a teleconference on the interim management statement to be held today,
Follow us:
Subscribe to BioGaia press releases here
LinkedIn here
Contacts:
Email: ako@biogaia.se
Phone: +46 (0) 735 00 11 11
Email: mis@biogaia.se
Phone: +46 (0) 730 95 61 50
About BioGaia
BioGaia is an innovative Swedish healthcare company that develops, markets, and sells probiotic products with documented health benefits. The products are sold through local distribution partners in more than 100 countries worldwide. The class B share of the
This disclosure contains information that BioGaia is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person set out above, at
https://news.cision.com/biogaia/r/biogaia-ab--interim-report-third-quarter-january---september-2022,c3652320
https://mb.cision.com/Main/3271/3652320/1641634.pdf
(c) 2022 Cision. All rights reserved., source